Literature DB >> 12804776

PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells.

Sukmi Kang-Park1, Yoon Ik Lee, Young Ik Lee.   

Abstract

The PTEN gene (phosphatase and tensin homologous on chromosome 10) is frequently mutated or deleted in a number of malignancies including human hepatocellular carcinoma (HCC). We reported previously that the hepatitis B virus X (HBx) protein, known to be a causative agent in the formation of HCC, activates insulin-like growth factor II (IGF-II) expression through Sp1 phosphorylation by protein kinase C (PKC) or mitogen-activated protein kinase (MAPK) signaling. In this report we demonstrate that the PTEN effect on HBx induced IGF-II activation in a hepatoma cell line. Expression of PTEN and IGF-II was inversely related in different hepatoma cell lines. PTEN expression induced decreased Sp1 DNA binding by dephosphorylating Sp1 and interfered with transcriptional transactivation of IGF-II by HBx in hepatoma cells. The protein phosphatase activity was involved in PTEN downregulation of IGF-II transcription through downregulation of MAPK, MAPK kinase phosphorylation and PKC translocation. Our data suggest that PTEN blocks Sp1 phosphorylation in response to HBx, by inactivating PKC, MAPK and MAPK kinase which eventually downregulate IGF-II expression, during the formation of HCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804776     DOI: 10.1016/s0014-5793(03)00535-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  PTEN in liver diseases and cancer.

Authors:  Marion Peyrou; Lucie Bourgoin; Michelangelo Foti
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 2.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

3.  Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.

Authors:  Zhi-Zhen Dong; Deng-Fu Yao; Deng-Bing Yao; Xin-Hua Wu; Wei Wu; Li-Wei Qiu; Dao-Rong Jiang; Jian-Hua Zhu; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

4.  Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and -β via the IGF-1 and the insulin receptors in breast cancer cells.

Authors:  A E Richardson; N Hamilton; W Davis; C Brito; D De León
Journal:  Growth Factors       Date:  2011-03-16       Impact factor: 2.511

5.  Computational identification of bioactive compounds from Cydonia oblonga Mill. against hepatocellular carcinoma by targeting pTEN and HBx-interacting protein.

Authors:  Elhan Khan; Iffat Zareen Ahmad
Journal:  J Mol Model       Date:  2022-06-17       Impact factor: 1.810

Review 6.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

7.  Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells.

Authors:  S Kalla Singh; D Moretta; F Almaguel; N R Wall; M De León; D De León
Journal:  Growth Factors       Date:  2007-12       Impact factor: 2.511

8.  Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells.

Authors:  Chang-Qi Zhu; Svetlana N Popova; Ewan R S Brown; Dalia Barsyte-Lovejoy; Roya Navab; Warren Shih; Ming Li; Ming Lu; Igor Jurisica; Linda Z Penn; Donald Gullberg; Ming-Sound Tsao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-28       Impact factor: 11.205

9.  Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.

Authors:  Rive Sarfstein; Yael Friedman; Zohar Attias-Geva; Ami Fishman; Ilan Bruchim; Haim Werner
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

10.  Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice.

Authors:  Ryan B Corcoran; Tal Bachar Raveh; Monique T Barakat; Eunice Y Lee; Matthew P Scott
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.